Dermata Therapeutics reported financial results for the quarter ended June 30, 2026, and announced a strategic pivot to commercialize direct-to-consumer skincare products. The company disclosed cash and cash equivalents of $4.4 million as of June 30, 2026, down from $7.5 million at year-end 2025, with net loss per share of $0.74 for the quarter. R&D expenses decreased to $0.2 million while SG&A increased to $2.8 million due to marketing and legal costs associated with its new brand. Dermata announced it will launch its first commercial product, Tome Foundational Treatment, on August 25, 2026, following a trade show debut in Las Vegas. The company operates in the dermatologic solutions and consumer skincare industry.